The PSYCH Investor Summit is an opportunity to engage with distinguished industry leaders, rising entrepreneurs and global psychedelics investors to share insights and help develop this emerging frontier.
Our global psychedelics industry event will also showcase expanding businesses looking for capital – delivering the industry’s most promising opportunities directly to investors & funds.
If you’re interested in raising capital for your business, take the opportunity to present to an international audience of investors during the summit, where you’ll be provided with in-event branding and a virtual booth.
As a new partner of PSYCH, your business profile will be also be featured as part of our psychedelics industry report, across our social media channels and our digital platforms.
Tryp Therapeutics begins manufacturing synthetically produced psilocybin.
Core One Labs set to apply for its first patent for production of synthetic psilocybin.
Revive Therapeutics closes bought deal offering of CA$23 million.
Head of Centre for Psychedelic Research, Robin Carhart-Harris, named on ‘2021 TIME100 NEXT’ list.
Mydecine announces closing of CA$17.25m bought-deal public offering.
ATMA Journey Centers launches Canada’s first psychedelic training programme.
Australia’s first psychedelic business to debut following ATAI Life Sciences and Bionomics partnership.
MindMed signs partnership with MindShift Compounds to expand psychedelic medicine pipeline.
Compass Pathways makes controversial patent application on administration of psychedelic therapy.
Strategic clinical-trial partnership announced between Havn Life and HealthTech Connex.
Silo Wellness expands psychedelic-retreat operations in Jamaica.
MindCure raises US$23m to fund psychedelics research and digital therapeutics platform.
CaaMTech receives approval of patent to combine psychedelics and cannabinoids.
Nova Mentis shipment of psilocybin to Italy approved by US DEA.
PharmaDrug has applied to the FDA to study the use of DMT on stroke victims.
Field Trip Health announces opening of a psychedelics research and cultivation facility in Jamaica.
The process of listing Core One Labs on the NASDAQ exchange begins.
During The PSYCH Symposium in November 2020, a panel of leading experts operating in psychedelics sector, discussed the challenges associated with removing the spiritual and ceremonial elements of psychedelic experiences as their use within a clinical setting increases.
Enjoy access to this full panel discussion, which includes an in-depth debate on this key cultural and commercial issue.
Democrats’ control of US government raises hopes of improving access to psychedelic medicines.
Cambridge, Massachusetts, votes to decriminalise psychedelics.
New Jersey governor signs bill to reclassify psilocybin and reduce possession charges.
Bill introduced in Texas to study psychedelic medicines for therapeutic use.
Iowa lawmaker makes second attempt to have psilocybin removed from list of controlled substances.
Last year, research conducted by PSYCH, which included a comprehensive survey of 1,000+ adults in the UK & the US, revealed strong support for the legalisation of psychedelic medicines.
Enjoy access to the full findings as featured in: The Psychedelics as Medicine Report: Second Edition, available for free, here.
USciences partners with Compass Pathways to open Drug Discovery Center.
Psychedelic medicines set to redefine future of antidepressant treatments.
Tryp Therapeutics readies trial to study use of synthetic psilocybin to reduce excessive appetite.
Lundquist Institute receives US$1.75 million grant to study psychedelic therapies.
Does the psychedelic-medicine research sector lack diversity?
Screening of documentary on leading psychedelic-medicines researcher set for debut.